Browsing Tag
New York Stock Exchange
235 posts
GSK agrees up to $750m Chimagen deal to deepen multiple myeloma pipeline
GSK is paying up to $750 million for a trispecific multiple myeloma asset, with early clinical data set to determine whether the deal creates value.
Reformation (NYSE: REF) lifts revenue 24% as adjusted EBITDA margin reaches 16.4%
Reformation delivered 24.1% second-quarter revenue growth and sharply higher profit in its first public earnings report, while a pre-IPO debt-funded shareholder dividend leaves investors with a more leveraged balance sheet.
GMR Solutions (NYSE: GMRS) reprices $2.9bn loan and plans $200m debt paydown
GMR Solutions is using approximately $200 million of cash to reduce its Term Loan B while cutting the interest spread by 50 basis points, targeting roughly $28 million of annual interest savings.
Kroger slashed its sales outlook and the stock still rose. What did investors see?
The Kroger Co. cut its full-year identical-sales forecast after second-quarter growth slowed to 0.2%, but maintained profit and cash-flow guidance as e-commerce and retail-media earnings strengthened.
Teva Pharmaceutical Industries moves to extend debt maturities as refinancing strategy accelerates
Teva Pharmaceutical Industries launches a new bond refinancing targeting costly 2027-2030 debt. Find out what it means for its $13 billion net debt.
Brady Corporation eyes $1.15bn revenue boost from newly acquired Honeywell productivity business
Brady Corporation targets 23% earnings growth after its $1.4 billion Honeywell acquisition. Find out how the deal reshapes its 2027 outlook.
NYSE: WELA filing puts KKR-backed Wella’s $2.29bn debt under investor scrutiny
Wella files for a US IPO with $2.94bn revenue and $522m adjusted EBITDA, but $2.29bn of debt will shape how investors value the beauty group at listing.
Polymarket is suddenly worth $21bn, and the hardest question is whether prediction markets are finance or gambling
Polymarket is seeking about $1 billion at a $21 billion valuation, with 1789 Capital committing roughly $300 million. The financing values the prediction-market platform at less than rival Kalshi but implies a paper value of about $4.6 billion for Intercontinental Exchange’s reported 22% stake. The harder question is whether billion-dollar annualised revenue can survive state-level legal battles, market-integrity scrutiny and a shift from speculative trading toward institutional financial infrastructure.
Wella’s IPO looks like a beauty growth story until the $2.29bn balance-sheet number enters the picture
Wella Company has filed for a New York Stock Exchange IPO after returning to profit and lifting adjusted EBITDA above $520 million. The owner of Wella Professionals, OPI, Clairol and ghd has delivered 22 consecutive quarters of constant-currency growth, but $2.29 billion of debt means the eventual valuation will depend as much on deleveraging as brand strength.
USI nearly tripled revenue under KKR, but Aon is paying 14.5 times synergised EBITDA for the next stage
Aon is paying $17 billion for privately held USI Insurance Services only two years after its $13 billion NFP acquisition. The transaction gives KKR a sixfold return on its original 2017 equity, but Aon’s 9.5% share-price fall shows investors are focusing just as closely on leverage, a 14.5-times synergised EBITDA multiple and the cost of integrating another major insurance brokerage.